June Ye

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.8K citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Richard E. Pratley, Michael A. Nauck, Anthony Barnett et al. · The Lancet Diabetes & Endocrinology · 2014 · 325 citations

Medicine, Pharmacology, Pharmacotherapy +17

Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)*

Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende et al. · Critical Care Medicine · 2019 · 245 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

Richard S. Hotchkiss, Elizabeth Colston, Sachin Yende et al. · Intensive Care Medicine · 2019 · 194 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +12

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

Peter N. Weissman, Molly C. Carr, June Ye et al. · Diabetologia · 2014 · 134 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12